Exposure-response modeling of the ACR20 score in rheumatoid arthritis patients treated with certolizumab pegol

被引：0
|
作者：
Lacroix, B. [1 ,2 ]
Lovern, M. [1 ]
Stockis, A. [1 ]
Sargentini-Maier, M. L. [1 ]
Karisson, M. O. [2 ]
Friberg, L. E. [2 ]
机构：
[1] UCB Pharma SA, Pharmacometr, Braine Lalleud, Belgium
[2] Uppsala Univ, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 48卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
42
引用
收藏
页码：1107 / 1107
页数：1
相关论文
共 50 条
  • [1] Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
    Lacroix, B. D.
    Karlsson, M. O.
    Friberg, L. E.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (10):
  • [2] A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis
    Lacroix, B. D.
    Lovern, M. R.
    Stockis, A.
    Sargentini-Maier, M. L.
    Karlsson, M. O.
    Friberg, L. E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) : 387 - 395
  • [3] AN EXPOSURE-RESPONSE MODEL CHARACTERIZING THE TIME-COURSE OF ACR20, ACR50, AND ACR70 IN RHEUMATOID ARTHRITIS (RA) PATIENTS ON BARICITINIB
    Choi, S.
    Macias, W. L.
    Tham, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S37 - S38
  • [4] Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
    Paul, Stephane
    Marotte, Hubert
    Kavanaugh, Arthur
    Goupille, Philippe
    Kvien, Tore K.
    de Longueville, Marc
    Mulleman, Denis
    Sandborn, William J.
    Vande Casteele, Niels
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (04): : 743 - 751
  • [5] Exposure-Response Modeling and Power Analysis of ACR Core Components in Rheumatoid Arthritis
    Zhang, Yi
    Ma, Lian
    Ji, Ping
    Yim, Sarah
    Doddapaneni, Suresh
    Liu, Jiang
    Dinko, Rekic
    Brar, Satjit
    Wang, Yaning
    Sahajwalla, Chandrahas
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S68 - S68
  • [6] Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol
    Saraux, Alain
    Flipo, Rene-Marc
    Fagnani, Francis
    Cukierman, Gabrielle
    Bru, Isabelle
    Joubert, Jean-Michel
    Schuller, Jan-Christof
    Massol, Jacques
    Combe, Bernard
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [7] Longitudinal exposure-response analysis of CDAI score in rheumatoid arthritis patients treated with sirukumab
    Xu, Yan
    Hu, Chuanpu
    Zhuang, Yanli
    Hsu, Benjamin
    Xu, Zhenhua
    Sharma, Amarnath
    Zhou, Honghui
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S121 - S121
  • [8] Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab
    Hu, Chuanpu
    Xu, Yan
    Zhuang, Yanli
    Hsu, Benjamin
    Sharma, Amarnath
    Xu, Zhenhua
    Zhang, Liping
    Zhou, Honghui
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 (05) : 679 - 691
  • [9] Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis
    Toyoshima, Junko
    Kaibara, Atsunori
    Shibata, Mai
    Kaneko, Yuichiro
    Izutsu, Hiroyuki
    Nishimura, Tetsuya
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (03):
  • [10] Evaluation of improvement in rheumatoid arthritis by the ACR20 criteria.
    Villanueva, L
    Toyos, FJ
    Ariza, R
    Grandal, Y
    Guzman, MM
    Navarro, F
    [J]. ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S206 - S206
12345